VJHemOnc Podcast

Laurence de Leval and other experts discuss advances in the treatment of T-cell lymphoma, including brentuximab vedotin in EATL, epigenetic drugs and TRBC1-directed CAR-T therapy, and developments in cutaneous T-cell lymphoma. Topics include CD30 targeting in intestinal T-cell lymphomas, Prantoxima beta protein in Italy PTCL, outcomes of auto transplant, exploring epigenetic drugs, and targeting CT2 mutations in aggressive T-cell lymphomas.

Experts Shaji Kumar and Ashutosh Wechalekar discuss highlights from the ISA 2022 meeting, including diagnostic approaches in AL amyloidosis, advances in imaging techniques, and the role of stem cell transplantation in the era of daratumumab-based therapies.

Expert guest Charlotte Pawlyn discusses managing high-risk and frail patients with myeloma, including treatment strategies and the importance of standardized definitions. They also highlight the prognostic value of measurable residual disease (MRD) and its application in clinical practice. The recent approval of teclistamab by the European Medicines Agency is also discussed.

Andrew Ku, an expert in myeloproliferative neoplasms (MPNs), discusses disease progression in MPNs, the importance of early intervention, and future targets at the 2022 Texas MPN Workshop. Topics covered include impeding disease progression, inflammation and TNF production in MPN patients, and the correlation between monocyte activity and disease progression.

Experts discuss key highlights from the 1st International Workshop on Myelodysplastic Syndromes, including immune dysregulation in MDS, improving drug approvals, treating high-risk disease, and challenges in the field. They also explore the significance of patient-related factors in clinical trial design, advancements in high-risk MDS trials, novel agents for lower risk MDS, and the challenges of drug access in different countries.

Heinz Ludwig, MD, and Meral Beksac, MD, discuss identifying high-risk myeloma patients and improving treatment strategies. They explore parameters for defining high-risk disease, the insufficiency of current risk definitions, and the debate on cytogenetic abnormalities. The speakers also delve into the identification of high-risk patients using reliable tools and discuss treatment strategies including quadriplet therapy and CAR-T. Furthermore, they highlight the significance of the microenvironment in managing high-risk myeloma and the need for further research.

Experts Hetty Carraway and Justin Taylor discuss improving drug approvals in MDS. They cover challenges of treating high-risk disease, novel targets of interest, and more. Collaboration between NCI and cooperative groups in clinical trials, biomarker significance, accelerating drug approvals, and individualizing treatment strategies are also explored.

Ruben Mesa, MD and Naveen Pemmaraju, MD discuss advances in MPN treatment, including therapies for essential thrombocythemia, polycythemia vera, and myelofibrosis. Topics include new drugs, biomarkers, and combination therapies. They also explore the implications of MPN treatment on broader health, such as cardiovascular mortality and cognitive health.

Experts discuss the challenges in developing effective first-line therapies for MDS. They explore IRAC inhibitors, combination approaches, CD47 antibodies, and CAR-T therapy in MDS treatment. The potential of CAR-TI immunotherapy in treating MDS is also discussed.

Gareth Morgan, Rafael Fonseca, Leif Bergsagel, and Keith Stewart discuss highlights from day two of the Myeloma 2022 meeting, covering topics such as BCL2 inhibitors, T-cell exhaustion, immunotherapy, targeted therapies, combination therapies, minimal residual disease, and the efficacy of Carti therapy in managing melon.